---
title: "Starcoin Group Plans Debt-Equity Deal to Cut Liabilities and Add Strategic Investor"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280913146.md"
description: "Starcoin Group Limited has signed a memorandum of understanding with Marvel Nice Limited for a potential debt-equity deal involving HK$715 million in convertible bonds. Marvel Nice would subscribe for new shares at a minimum of HK$1 per share, offsetting the bonds' principal and interest. This transaction aims to reduce Starcoin's liabilities, attract a strategic investor, and enhance its financial position for its beauty products and oral insulin businesses. The deal is expected to broaden the company's shareholder base and support future growth opportunities."
datetime: "2026-03-29T11:38:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280913146.md)
  - [en](https://longbridge.com/en/news/280913146.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280913146.md)
---

# Starcoin Group Plans Debt-Equity Deal to Cut Liabilities and Add Strategic Investor

### End of Quarter Sale - 50% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Innovative Pharmaceutical Biotech ( (HK:0399) ) has shared an update.

Starcoin Group Limited has signed a memorandum of understanding with Hong Kong-incorporated Marvel Nice Limited for a possible share subscription, following Marvel Nice’s intended acquisition of HK$715 million in convertible bonds previously issued by the company. Under the non-binding terms, Marvel Nice would subscribe for new shares at no less than HK$1 per share, with the subscription price to be settled by offsetting the outstanding principal and interest of the bonds.

If completed, the transaction would substantially reduce Starcoin’s liabilities, bring in a new strategic shareholder and bolster its financial position for ongoing development of its beauty products trading and oral insulin businesses. The board believes the potential deal would broaden the company’s shareholder and capital base, provide additional funding capacity and create room for future business development opportunities, positioning the group for more diversified growth.

The most recent analyst rating on (HK:0399) stock is a Sell with a HK$0.12 price target. To see the full list of analyst forecasts on Innovative Pharmaceutical Biotech stock, see the HK:0399 Stock Forecast page.

**More about Innovative Pharmaceutical Biotech**

Starcoin Group Limited, formerly Innovative Pharmaceutical Biotech Limited, is an investment holding company whose group operations focus on trading beauty products in Hong Kong and on the research, development and commercialisation of an oral insulin product. The company is seeking to diversify risk, broaden income sources and improve cash reserves while strengthening its shareholder and capital base.

**Average Trading Volume:** 42,228,277

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$452.8M

### Related Stocks

- [00399.HK](https://longbridge.com/en/quote/00399.HK.md)

## Related News & Research

- [Celebrity Makeup Artist Sir John Teams Up with Mattress Firm on Beauty Sleep Edit | SGI Stock News](https://longbridge.com/en/news/286926335.md)
- [Novvia Group Acquires APC Packaging](https://longbridge.com/en/news/286948675.md)
- [Premium skincare brand Forest Cabin will study L’Oreal, but not copy it: CEO interview](https://longbridge.com/en/news/286831488.md)
- [00:01 ETBeauty's Next Wave Sees Consumers Adding Aesthetic Procedures and Longevity Treatments to Regular Routines](https://longbridge.com/en/news/286193601.md)
- [11:47 ETThe Skincare Boom Has a Talent Gap -- Tricoci University of Beauty Culture is Training the Next Generation](https://longbridge.com/en/news/286289053.md)